267 results about "Murine monoclonal antibody" patented technology

A reshaped antibody comprising: (A) L chains comprising: (1) a human C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of a mouse monoclonal antibody; and (B) H chains comprising: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs, and H chain CDRs of a mouse monoclonal antibody to human IL-6. Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6.

The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and / or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and / or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and / or compositions comprising such antibodies in combination with anti-EGFR antibodies and / or compounds and / or anti-cancer agents or agents conjugated with toxins and their use for the prevention and / or the treatment of certain cancers.

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to B7H4 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided, immunoconjugates, including antibody-drug conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.

The invention relates to a mouse monoclonal antibody of anti-human carcino-embryonic antigen (CEA) resisting colorectal neoplasm activity, prepared by a biological technology. The method comprise a method for detecting CEA family protein by utilizing the antigen-combining capacity specificity of the mouse monoclonal antibody CC4 of anti-human CEA and a neoplasm treatment method by utilizing the colorectal neoplasm activity. The antibody can be used for specifically recognizing the human CEA at molecular, cellular and texture levels and recognizing a special antigen epiposition widely distributed in the CEA family protein. The CC4 is specifically combined with colorectal neoplasm texture at the texture level and presents stronger capabilities of restraining neoplasm growth, neoplasm metastasis, neoplasm invasion in an animal model and at the cellular level. The antibody and detection and treatment methods based on the antibody can become an effective neoplasm diagnosis and treatment tool in basal research or clinical application.

The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.

The invention discloses a humanized monoclonal antibody targeting to human CD19 antigen. The humanized monoclonal antibody is applied to construction and preparation of chimeric antigen receptor T cells; and subsequent in-vitro experiments verify the tumor treatment effect of the chimeric antigen receptor T cells. A chimeric antigen receptor targeting to the human CD19 antigen is composed of a leader peptide, a single-chain antibody targeting to the human CD19 antigen, a hinge area for connection with ScFv, a transmembrane domain and an immune receptor tyrosine activation motif; a lentiviral expression vector is constructed from the chimeric antigen receptor and then used for infection of immune cells, so the chimeric antigen receptor targeting to the human CD19 antigen can be expressed in the immune cells; and tumors expressing the CD19 antigen are killed by recognizing the CD19 antigen on the surfaces of tumor cells, so the purpose of tumor treatment is achieved. The invention provides a novel tool for targeting therapy of tumors.

The invention provides a variable region sequence for a rat monoclonal antibody specially combined with porcine epidemic diarrhea viruses, a prepared antibody or an antibody fragment thereof, and vaccine and a kit prepared from the antibody. The medicine composition can effectively prevent and treat porcine epidemic diarrhea virus infection. The kit can effectively detect the porcine epidemic diarrhea viruses, is high in sensitivity, and carry out detecting fast.

The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the grown of CD30+ cells, such as tumor cells, are also provided.

The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10) produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specific binding to the antigen of the original antibodies, but being at the same time less immunogenic. The chimeric antibodies of the invention contain the variable domains of the murine immunoglobulin and the constant regions of the human immunoglobulin; and those humanized, besides containing the constant regions of the human immunoglobulins, they are modified in the region of the murine frameworks (FRs) and in particular in those zones that could be in an antigenic site for the T cells, so several positions of the FRS are human as well. These antibodies can be used in the diagnosis and therapy of different types of tumors. The present invention is also related with use of the antibodies for therapeutical and diagnostic purposes.

This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human / murine chimeric antibody, ChiBR96; a F(ab')2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab')2-LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

The invention provides an anti-CD19 monoclonal antibody, and a preparation method and an application thereof. The anti-CD19 monoclonal antibody can effectively recognize cells with CD19 highly expressed, and can be successfully used for Western Blot detection. An affinity test shows that the monoclonal antibody has the extremely high affinity to target protein.

The invention discloses a preparation method of anti-fluoroquinolone rabbit monoclonal antibodies and application thereof. Six fluoroquinolone medicaments are chosen in the invention and coupled with Bovine serum albumin (BSA) to synthesize immunoantigens respectively. The above six immunoantigens are injected subcutaneously in the backs of immune rabbits after being mixed together. The anti-fluoroquinolone rabbit monoclonal antibodies are obtained by hybridoma technique. Rabbit monoclonal antibodies, which are superior to rat monoclonal antibodies, are prepared in the invention. More antigenic determinants are identified when rabbits are chosen as the experimental animal instead of rats. In addition, more integrated experiments can be carried out in rabbit spleens, since the spleens of rabbits are larger than that of rats. The invention provides the possibility of high throughput screening for fusion cells. The anti-fluoroquinolone antibodies of wide-adaptability in the invention has good detection effect on fluoroquinolones, such as enrofloxacin, ofloxacin, Difloxacin, Pefloxacin, Fleroxacin, Danofloxacin, etc., thus making it applicable to fluoroquinolone residue detection on food, forage and environmental samples.

The present invention discloses a humanized monoclonal antibody and an application thereof, belonging to the technical field of medicine. In the invention, the humanized transformation is carried outon a rat monoclonal antibody 2A10G6, the rat monoclonal antibody 2A10G6 is expressed by baculovirus, and the humanized antibody h2A10G6 is obtained. The h2A10G6 antibody of the present invention has high affinity and neutralization activity against yellow fever virus, dengue fever and West Nile virus, and can be applied to clinical treatment and prevention of yellow fever virus, dengue virus and West Nile virus.

The invention relates to methods of treatment using combination therapy wherein a variety of therapeutically useful compounds may be combined with antibodies which bind to insulin-like growth factor receptor-1 (IGF-1R). Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention particularly includes methods of treating cancer using combination therapies with IGF-1R antibodies.

This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and / or treatment of RSV infection.

The invention discloses a test paper for qualitative semi-quantitative dual-purpose detection of female ovulation, which is formed mainly by overlapping and connecting a bottom plate, a nitrocellulose membrane, an absorption pad, a polyester film and a glass fiber membrane mutually, wherein the middle of the bottom plate is adhered with the nitrocellulose membrane on which two antibody lines are engraved, one line is a detection line coated by a first anti-LH monoclonal antibody, and the other line is a quality control line coated by goat anti mouse IgG monoclonal antibody; and the upper edge position of the nitrocellulose membrane is adhered with the water absorption pad, the lower edge position of the nitrocellulose membrane is adhered with a combined pad which combines another anti-LH monoclonal antibody of marking colloidal gold or color rubber latex, and the lower edge position of the combined pad is adhered with a sample pad. A woman can use the test paper of the invention at home to qualitatively and semi-quantitatively detect the content of LH luteinizing hormone of the urine or blood of the woman, and knows the ovulation date, or knows whether hormonal infertility exists or not.

The present invention provides stable liquid formulations comprising chimeric and humanized versions of anti-CD 19 mouse monoclonal antibodies that may mediate ADCC, CDC, and / or apoptosis for the treatment of B cell diseases and disorders.

The invention discloses a murine monoclonal antibody resistant to human vascular endothelial growth factors (VEGFs), a combination reagent containing the murine monoclonal antibody and used for detecting the human VEGF level in a biological sample, a reagent box containing the combination reagent and a use method of the reagent box. The combination KD value of the murine monoclonal antibody and the human VEGFs reaches 0.01 nM, and the combination reagent containing the murine monoclonal antibody and the reagent box containing the combination reagent have the advantages of being high in detection sensitivity and specificity.

The invention relates to a test paper card for detecting porcine transmissible gastroenteritis virus antibody, preparation and detection method thereof, and belongs to the field of immunological detection. The test paper card includes a jammed case and a test strip, and the test strip includes a bottom plate and sequentially lapped and pasted on the Absorbent pad, detection pad, binding pad and sample pad on the base plate; the detection pad is a nitrocellulose membrane with a quality control line C and a detection line T, the quality control line C is coated with goat anti-mouse monoclonal antibody, and the detection line T is Coated with inactivated porcine transmissible gastroenteritis virus; the binding pad is a glass cellulose membrane embedded with time-resolved fluorescent microsphere-labeled anti-E2 protein monoclonal antibody; the sample pad is dried glass after soaking in the sample treatment solution Cellulose film. The test paper card prepared by the invention has better stability and higher sensitivity, and can achieve the purpose of semi-quantitative detection through fluorescence signal analysis.

The invention discloses a rapid detection quantum dot immunochromatographic test strip, a kit, a preparation method and a use method. Phosphorylated VASP protein murine monoclonal antibodies and quantum dot conjugates are sprayed onto glass fiber membranes to obtain a probe fixation mat, the VASP protein murine monoclonal antibodies are enveloped on a detection membrane detection line, goat-anti-mouse polyclonal antibodies are enveloped on a detection membrane quality control line, a detection membrane, the probe fixation mat, a sample mat and absorbent paper are sequentially assembled on a PVC (polyvinyl chloride) substrate, and the substrate is cut into small strips to obtain the test strip. The quantum dot immunochromatographic test strip is simple and convenient to operate, high in sensitivity and accuracy, low in cost and suitable for clinical rapid detection.

The present invention relates to a group of anti-human CD146 molecules developed by using a biological technology and an established high sensitivity sandwich ELISA method for soluble CD146 detection. The present invention provides anti-human CD146 mouse monoclonal antibodies (AA1, AA2, AA3, AA4, AA5 and AA7), and a method for specially detecting soluble CD146 by using antibody combinations and sandwich ELISA, wherein the antibodies can specifically recognize human source CD146 at a molecular level, a cellular level and a tissue level, and can be divided into two classes based on recognition of different epitopes. With an antibody AA1 and anti-human CD146 mouse monoclonal antibody AA98 combined sandwich ELISA method, nanogram-scale soluble CD146 in per ml of the solution can be detected. The antibodies and the detection method can become effective detection or diagnosis tools and methods in basic researches or clinical applications, and can further provide good carriers for targeted therapies of CD146-related diseases.

The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications in the field of breast cancer. The present invention also provides methods for the humanization of antibodies such as murine monoclonal antibodies. The novel humanization methods are applied to the production of humanized Mc3 antibodies and it is shown that these humanized antibodies retain the ability to engage in high affinity binding to their cognate antigen. Such humanization enables the use of these antibodies for immunodiagnostic and immunotherapeutic applications in humans.

The invention relates to the technical field of biology and particularly discloses a human anti-CD20 monoclonal antibody and a preparation method and application thereof. In the preparation method, a large-capacity natural human phage antibody library is constructed and the antibody library is screened to obtain a human anti-CD20 antibody 3C5, wherein the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:6 and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8. In addition, the invention also discloses a preparation method of the antibody 3C5, a nucleotide sequence coding the antibody 3C5 and an expression vector and host cell containing the nucleotide sequence. Compared with the other anti-CD20 antibodies, the human monoclonal antibody 3C5 has higher antibody affinity and ADCC and CDC activities; and the antibody 3C5 can be used to prepare anticancer medicaments.

This invention relates to a method for testing S. aureus in a specimen by an immunoassay using an antibody against protein A wherein at least one mouse IgG1 monoclonal antibody is used in the immunoassay, and a test kit for testing S. aureus in a specimen wherein the kit at least comprises a mouse IgG1 anti-protein A monoclonal antibody and a reagent for detecting the labeled protein A. Use the present invention enables detection of S. aureus in the sample in a short time and at a high sensitivity.